Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07331987

Efficacy and Safety of Probiotics for Anxiety Depression

This randomized, double-blind, placebo-controlled study will enroll 60 individuals with mild-to-moderate anxiety depression. Following a 3-month intervention and a 1-month follow-up period, the study aims to: 1) evaluate the efficacy of probiotics by comparing anxiety, depression, and sleep scores to baseline; and 2) investigate the safety and underlying mechanisms by analyzing changes in serum biomarkers, gut microbiota, and related metabolites.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Guangdong Pharmaceutical University

Guangzhou, Guangdong, China

Location status: Recruiting

Location contact

IRB, First Affiliated Hosp, Guangdong Pharm Univ

CONTACT

[email protected]

86-020-87609616

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) Age: 18-60 years old; Gender: male or female.
  • 2) Meets the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for a mild-to-moderate depressive or anxiety symptoms.
  • 3) Hamilton Depression Rating Scale (HAM-D-24) score ≥ 8 or Hamilton Anxiety Rating Scale (HAM-A-14) score ≥ 7 at screening.
  • 4) Has no used of anxiolytic or antidepressant medications (including traditional Chinese patent medicines), with the exception of Escitalopram Oxalate, within 2 weeks prior to the first dose.
  • 5) For participants of childbearing potential (male or female): Must agree to use least one medically approve form of contraception (e.g., intrautering device [IUD], oral contraceptives, or condoms) throughout the trial. For female participants of childbearing potential: Must have a negative urine pregnancy test at screening and must be non-lactating.
  • 6) The participant is willing and be able to provide written informed consent to participate in the study.

Exclusion criteria

  • 1) HAM-D-24 score ≥ 35 or HAM-A-14 score ≥ 29.
  • 2) Presence of significant suicidal ideation.
  • 3) History or current diagnosis of neuropsychiatric disorders such as schizophrenia or epilepsy.
  • 4) History of head trauma (with loss of consciousness for >10 minutes), other unstable major somatic diseases, or any somatic condition that could cause psychiatric symptoms.
  • 5) Suspected intellectual disability.
  • 6) History of alcohol or substance abuse prior to enrollment.
  • 7) Cranial magnetic resonance imaging (MRI) reveals organic lesions.
  • 8) Participants who are deemed unsuitable for the study by the investigator for any other reason.

Treatment and study plan

Probiotic

Drug

Participants receive Probiotic product once daily by oral, 60B CFU/day for 3 months.

Placebo

Drug

Participants receive Placebo once daily by oral for 3 months.

Escitalopram

Combination Product

Participants receive Escitalopram Oxalate Tablets once daily by oral, 10mg/day for 3 months.

Primary outcomes

  1. Hamilton Depression Rating Scale (HAM-D-24)

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

    Depression symptoms will be assessed using the 24-item Hamilton Depression Rating Scale (HAM-D-24) at baseline and the specified time points during the study. With higher scores indicating more severe depression, and scores categorized as <8 non-depressed, 8-19 mild, 20-34 moderate, ≥35 severe for diagnosis and monitoring treatment response.

  2. Hamilton Anxiety Rating Scale (HAM-A)

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

    Anxiety symptoms will be evaluated using 14-item Hamilton Anxiety Rating Scales (HAM-A) at baseline and the specified time point during the study. Each item is scored on a scale of 0 (not present) to 4 (severe). The total score, calculated by summing all items, ranges from 0 to 56, with higher scores indicating greater anxiety severity, where 0-7 indicates no/minimal, 8-14 mild, 15-23 moderate and ≥24 severe.

Secondary outcomes

  1. The Pittsburgh Sleep Quality Index (PSQI)

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

    Assesses sleep quality from baseline to end of the study by questionnaire of The Pittsburgh Sleep Quality Index (PSQI). There are 19 items that are used to generate 7 component scores, which then are added together to determine a global score that ranges between 0 to 21, where higher scores reflect worse sleep quality.

  2. Gastrointestinal Symptom Rating Scale (GSRS)

    Time frame: Baseline, Day 30, Day 90, Day 120 (follow up)

    Assessment of gastrointestinal symptoms will conducted at baseline and throughout the study period. The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.

Study contacts

Contact information is provided by the study sponsor or research team.

Baojia Huang

CONTACT

[email protected]

86-020-31603387

Sponsors and collaborators

Lead sponsor

Moon (Guangzhou) Biotechnology Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Efficacy and Safety of Probiotics in Participants With Anxiety Depression

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 12, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.